RecruitingNot ApplicableNCT07026890

The Benefits of Virtual Reality in the Care of Elderly People With Psychomotor Disadaptation Syndrome

The Value of Virtual Reality in the Care of Elderly People With Psychomotor Disadaptation Syndrome: a Randomised Controlled Trial of Mixed Efficacy and Implementation vs. Conventional Rehabilitative Care


Sponsor

Centre Hospitalier Universitaire Dijon

Enrollment

50 participants

Start Date

Jul 16, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Psychomotor Disadaptation Syndrome (PMDS) is characterised by a deterioration in postural function, gait and psychomotor automatisms in the elderly. It is often associated with falls and can manifest itself as retropulsion, gait abnormalities, neurological disorders and psycho-behavioural problems. For the majority of these patients, a stay in a geriatric medical and rehabilitation centre is necessary, enabling an objective assessment of these disorders and multi-professional care, including physiotherapists, occupational therapists and adapted physical activity teachers, aimed at restoring safe movement and motor independence. However, rehabilitation relies on traditional exercises that are limited, repetitive and sometimes far removed from everyday activities. Technological innovations such as virtual reality (VR) offer opportunities to improve care by creating immersive environments that reproduce real-life situations. VR could thus help to rehabilitate the motor problems associated with MS. The aim of the VIR-AGE project is to study the clinical benefits of VR in the rehabilitation of hospitalised elderly people suffering from PMDS in terms of functional deficits, particularly motor deficits. The study will take place at the Centre gériatrique Champmaillot of the CHU Dijon Bourgogne. A total of 50 patients with SPDM will take part. The total duration of your participation is 5 weeks.


Eligibility

Min Age: 65 Years

Inclusion Criteria5

  • Person who has given written consent
  • Person aged ≥ 65 years;
  • With a proven diagnosis of motor maladjustment syndrome;
  • Hospitalised in a geriatric care unit;
  • Able to understand a simple instruction and answer a closed question;

Exclusion Criteria14

  • Person not affiliated to or not benefiting from a social security scheme
  • Person subject to a legal protection measure (curatorship, guardianship)
  • Person subject to a judicial protection measure
  • An adult who is incapable or unable to give consent
  • Persons with epilepsy, kinetosis or known claustrophobia Persons unable to understand simple instructions for carrying out tests
  • Anyone with a severe visual and/or hearing impairment
  • Any person with a behavioural disorder (agitation, aggressiveness)
  • Any person with a severe walking or balance problem that makes motor exercises unsuitable
  • Anyone with a pathology, injury, wound or severe deformity to the head or cervical spine
  • Any person suffering from severe vertigo, diagnosed at the discretion of the investigating doctor
  • Inability to use arm for pointing
  • Persons susceptible to migraines
  • Non-French speakers
  • Anyone with an inter-pupillary distance outside the range of possible helmet adjustments

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHEREvaluation visits

3 assessment visits (initial (V1), intermediate (V2) and final (V3). A series of motor assessments carried out by the physiotherapist: * Timed Up and Go Test (TUG) * 10 m walk test (TM10) * Functional Reach Test (FRT) * Minimum Motor Test (TMM) * 10 m walk test combined with a verbal task such as naming different animals

OTHERRehabilitation sessions

Usual treatment: 4 to 5 rehabilitation sessions per week, each lasting 45 minutes.

OTHERVirtual reality sessions

3 virtual reality sessions per week, each lasting 30 minutes.

OTHERAdditional rehabilitation sessions

3 additional rehabilitation sessions per week. These sessions correspond to standard rehabilitation sessions.


Locations(1)

CHU Dijon Bourgogne

Dijon, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07026890